X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

Content Team by Content Team
9th November 2022
in Clinical Trials, News

In the first clinical trial of its sort, lab-grown blood cells were administered to a second patient, potentially paving the way for future therapies for blood disorders like sickle cell.

At the NHS Blood and Transplant (NHSBT) Advanced Therapies Unit in Bristol, stem cells from blood donors were purified and expanded to make modified red blood cells. The NHSBT and the University of Bristol’s Red Blood Cell Products Research Unit from the National Institute for Health and Care Research (NIHR) are in charge of the study.

The longevity of the transformed cells was compared to regular red blood cell infusion from the same donor in the randomised, controlled clinical experiment RESTORE. Red blood cells from regular donors used in similar transfusions come in a range of ages. However, because the lab-grown blood cells are new, scientists anticipate that the therapy will work more effectively. They believe people who require frequent blood transfusions may eventually need less. Their chance of developing serious problems from iron overload, a risk of frequent blood transfusions, should decrease with the new therapy.

The trial’s participants experienced no negative side effects.

Red Blood Cells Made In A Lab Used For Clinical Trials

Ten or more trial participants will receive two mini-transfusions, spaced at least four months apart, if they have unusual blood types or complex transfusion requirements. The infusion of lab-grown blood cells might range in volume from five to ten milliliters. One transfusion of regular blood cells and one of lab-grown blood cells will be given by the researchers. This will enable researchers to test whether modified cells outlive naturally occurring ones.

This research offers great promise for those hard-to-transfuse sickle cell patients who have evolved antibodies to most donor blood types, said Chief Executive of the Sickle Cell Society, John James OBE.

Patients who need frequent or infrequent blood transfusions may, as a result, develop antibodies against minor blood groups, making it harder to find donor blood that can be transfused without such a risk of a potentially life-threatening reaction, said the Medical Director of Transfusion for NHS Blood and Transplant, Dr. Farrukh Shah.

This discovery marks a milestone for patients and means that therapy for those with disorders such as sickle cell could change, said Neil O’Brien, Minister of State for Health. Specialists from Guy’s and St. Thomas’ NHS Foundation Trust and the University of Cambridge, the NIHR Cambridge Clinical Research Facility, and Cambridge University Hospitals NHS Foundation Trust all worked together on the study, which was partially financed by the NIHR.

Previous Post

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

Related Posts

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022

Latest News

Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In